Hypera Stock Forecast, Price & News

Hypera (OTCMKTS:HYPMY) Frequently Asked Questions

What stocks does MarketBeat like better than Hypera?

Wall Street analysts have given Hypera a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hypera wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hypera?

Hypera saw a decrease in short interest in August. As of August 31st, there was short interest totaling 2,800 shares, a decrease of 46.2% from the August 15th total of 5,200 shares. Based on an average daily trading volume, of 33,400 shares, the days-to-cover ratio is presently 0.1 days.
View Hypera's Short Interest.

How has Hypera's stock been impacted by Coronavirus?

Hypera's stock was trading at $6.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HYPMY shares have decreased by 14.0% and is now trading at $6.0050.
View which stocks have been most impacted by COVID-19.

Is Hypera a good dividend stock?

Hypera pays an annual dividend of $0.16 per share and currently has a dividend yield of 2.64%.
View Hypera's dividend history.

Who are Hypera's key executives?

Hypera's management team includes the following people:

• Mr. Breno Toledo Pires de Oliveira, Chief Exec. Officer
• Mr. Adalmario Ghovatto Satheler do Couto, Investor Relations Officer & CFO
• Mr. Carlos Roberto Scorsi, Chief Operating officer (Age 59)
• Juliana Aguinaga Damião Salem, Chief Legal & Compliance Officer
• Mr. Luiz Eduardo Sales Clavis, Commercial & Marketing VP
• Mr. Nelson José de Mello, Chief Corp. Relations Officer (Age 62)
• Mr. Hélio Segouras, Head of Consumer Health
• Mr. Claudio Bergamo dos Santos, Pres of Pharma & Director (Age 56)
• Mr. Martim Prado Mattos, Sec. (Age 41)
• Mr. Luiz Eduardo Violland, Chief Exec. Officer of the Pharmaceutical Division

Who are some of Hypera's key competitors?

Some companies that are related to Hypera include BioMarin Pharmaceutical (BMRN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), CureVac (CVAC), Grifols (GRFS), Zai Lab (ZLAB), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Ascendis Pharma A/S (ASND), Biohaven Pharmaceutical (BHVN), Evotec (EVTCY), United Therapeutics (UTHR) and Jazz Pharmaceuticals (JAZZ).
View all of HYPMY's competitors.

What is Hypera's stock symbol?

Hypera trades on the OTCMKTS under the ticker symbol "HYPMY."

How do I buy shares of Hypera?

Shares of HYPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hypera's stock price today?

One share of HYPMY stock can currently be purchased for approximately $6.01.

How much money does Hypera make?

Hypera has a market capitalization of $3.80 billion and generates $793.81 million in revenue each year.

How many employees does Hypera have?

Hypera employs 8,918 workers across the globe.

What is Hypera's official website?

The official website for Hypera is www.hyperapharma.com.br.

Where are Hypera's headquarters?

Hypera is headquartered at AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120.

How can I contact Hypera?

Hypera's mailing address is AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120. The company can be reached via phone at 55-11-3627-4206 or via email at [email protected].